当前位置： SCI文献检索 > BMC HEALTH SERVICES RESEARCH期刊下所有文献 > Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE).

Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE).

Abstract：

BACKGROUND:The extent to which a genomic test will be used in practice is affected by factors such as ability of the test to correctly predict response to treatment (i.e. sensitivity and specificity of the test), invasiveness of the testing procedure, test cost, and the probability and severity of side effects associated with treatment. METHODS:Using discrete choice experimentation (DCE), we elicited preferences of the public (Sample 1, N = 533 and Sample 2, N = 525) and cancer patients (Sample 3, N = 38) for different attributes of a hypothetical genomic test for guiding cancer treatment. Samples 1 and 3 considered the test/treatment in the context of an aggressive curable cancer (scenario A) while the scenario for sample 2 was based on a non-aggressive incurable cancer (scenario B). RESULTS:In aggressive curable cancer (scenario A), everything else being equal, the odds ratio (OR) of choosing a test with 95% sensitivity was 1.41 (versus a test with 50% sensitivity) and willingness to pay (WTP) was $1331, on average, for this amount of improvement in test sensitivity. In this scenario, the OR of choosing a test with 95% specificity was 1.24 times that of a test with 50% specificity (WTP = $827). In non-aggressive incurable cancer (scenario B), the OR of choosing a test with 95% sensitivity was 1.65 (WTP = $1344), and the OR of choosing a test with 95% specificity was 1.50 (WTP = $1080). Reducing severity of treatment side effects from severe to mild was associated with large ORs in both scenarios (OR = 2.10 and 2.24 in scenario A and B, respectively). In contrast, patients had a very large preference for 95% sensitivity of the test (OR = 5.23). CONCLUSION:The type and prognosis of cancer affected preferences for genomically-guided treatment. In aggressive curable cancer, individuals emphasized more on the sensitivity rather than the specificity of the test. In contrast, for a non-aggressive incurable cancer, individuals put similar emphasis on sensitivity and specificity of the test. While the public expressed strong preference toward lowering severity of side effects, improving sensitivity of the test had by far the largest influence on patients' decision to use genomic testing.

journal_name

BMC Health Serv Res

journal_title

BMC health services research

authors

Najafzadeh M,Johnston KM,Peacock SJ,Connors JM,Marra MA,Lynd LD,Marra CA

doi

10.1186/1472-6963-13-454

subject

Has Abstract

pub_date

2013-10-31 00:00:00

pages

454

issn

1472-6963

pii

1472-6963-13-454

journal_volume

pub_type

杂志文章

在线工具

Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE).